Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T12:25:15.897Z.
Calculation as of: 2026-10-06T12:25:15.897Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6c856baf2af26ca9326fa79b8c43a58fbb1378fdf70f4049426595b89831cd0b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$1.96B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.00B
Price/FCF Ratio
792.16
TTM Avg
497.87
3Y Avg
11182.67
5Y Avg
11182.67
Market Cap
$2.01B
Price/FCF Ratio
13.33
TTM Avg
9.83
3Y Avg
12.32
5Y Avg
13.49
Market Cap
$1.89B
Price/FCF Ratio
N/A
TTM Avg
547.75
3Y Avg
444.15
5Y Avg
642.22
Market Cap
$2.02B
Price/FCF Ratio
11.65
TTM Avg
15.26
3Y Avg
21.56
5Y Avg
21.56
Market Cap
$1.87B
Price/FCF Ratio
N/A
TTM Avg
44.84
3Y Avg
44.84
5Y Avg
44.84
Market Cap
$2.05B
Price/FCF Ratio
17.47
TTM Avg
21.03
3Y Avg
765.32
5Y Avg
894.72
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Absci Corporation (ABSI) | $1.95B | N/A | N/A | N/A | N/A |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.96B | N/A | N/A | N/A | N/A |
| Azenta, Inc. (AZTA)vs › | $1.97B | 199.33 | 56.48 | 95.26 | 92.20 |
| AxoGen, Inc. (AXGN)vs › | $2.00B | 792.16 | 497.87 | 11182.67 | 11182.67 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.01B | 13.33 | 9.83 | 12.32 | 13.49 |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | N/A | 547.75 | 444.15 | 642.22 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 11.65 | 15.26 | 21.56 | 21.56 |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | N/A | 44.84 | 44.84 | 44.84 |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.05B | 17.47 | 21.03 | 765.32 | 894.72 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.06B | 5.76 | 22.88 | 35.76 | 35.76 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
